SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the immediate availability of a transformative addition to its industry-leading next-generation sequencing portfolio with the launch of the NextSeq 500 System. The new sequencer packs high-throughput performance into an affordable desktop form factor, enabling researchers to perform the most popular sequencing applications in less than a day. The NextSeq 500 System is priced at $250,000.
“Illumina’s sequencing portfolio is the most comprehensive in the world, and the addition of the NextSeq 500 System furthers this distinction by enabling next-generation sequencing to become an everyday tool,” said Jay Flatley, CEO of Illumina. “The NextSeq 500 was reimagined from the ground up and uses technology breakthroughs in optics, fluidics and chemistry to bring high throughput power to the desktop at a significantly reduced cost.”
NextSeq 500 System – Flexible Power
The NextSeq 500 System delivers the power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, effectively transforming a broad range of high-throughput applications into affordable, everyday research tools. Its push-button operation delivers a one-day turnaround for a number of popular sequencing applications, including one whole human genome and up to 16 exomes, up to 20 non-invasive prenatal testing samples, up to 20 transcriptomes, up to 48 gene expression samples and up to 96 targeted panels. With its streamlined informatics, sequencing data can be run through a range of open source or commercial pipelines or instantly transferred, analyzed, and stored securely in BaseSpace® or the new BaseSpace® OnSite for researchers needing an on premises solution.
Users also have the flexibility to switch to lower throughput sequencing as needed, and while other platforms require several pieces of specialized equipment, the NextSeq 500 System integrates cluster generation and sequencing into a single instrument. Data is generated in as little as 12 hours for a 75 cycle sequencing run and less than 30 hours for paired 150 cycle reads.
The new system is supported by the full suite of Illumina sample preparation and target enrichment solutions, offering library compatibility across the entire Illumina sequencing portfolio. Its configurable output supports a wide range of applications and sample sizes with the accuracy of Illumina sequencing by synthesis (SBS) technology.
Unrivaled Sequencing Portfolio
Illumina’s sequencing portfolio delivers the broadest range of applications, with standard workflow and chemistries across platforms. Illumina’s systems are the production platform of choice for all major genome centers and leading institutions around the world:
- HiSeq X™ Ten is the world’s first system to deliver full coverage genomes for less than $1,000. Purpose-built for large-scale human whole genome sequencing, it enables population-scale sequencing of tens of thousands of samples per year with high-quality, high-coverage SBS data, delivering a comprehensive catalog of human variation within and outside coding regions.
- HiSeq® 2500 System is the proven high-throughput powerhouse that enables efficient sequencing and large-scale studies at low operating costs. In Q2 2014, with the addition of recently announced 1T kit capabilities, many currently installed HiSeq systems will be capable of producing 1 terabase of sequencing data and run up to 10 whole human genomes in six days.
- MiSeq® System delivers low-complexity, targeted, small-genome sequencing for individual scientists who need a higher-quality view than they can get with capillary electrophoresis, PCR, or any competing offering.
- MiSeqDx™ System, designed specifically for clinical laboratories, is the first FDA-cleared in vitro diagnostic next-generation sequencing system.
The NextSeq 500 System is now shipping. For more information, visit www.illumina.com/nextseq.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.